Paul R. Kirchgraber M.D.
Net Worth

Last updated:

What is Paul R. Kirchgraber M.D. net worth?

The estimated net worth of Dr. Paul R. Kirchgraber M.D. is at least $14,520,208 as of 19 May 2023. He owns shares worth $3,570,248 as insider, has earned $3,949,960 from insider trading and has received compensation worth at least $7,000,000 in Laboratory Corporation of America Holdings.

What is the salary of Paul R. Kirchgraber M.D.?

Dr. Paul R. Kirchgraber M.D. salary is $1,400,000 per year as Executive Vice President & Chief Executive Officer of Covance Drug Devel. in Laboratory Corporation of America Holdings.

How old is Paul R. Kirchgraber M.D.?

Dr. Paul R. Kirchgraber M.D. is 63 years old, born in 1962.

What stocks does Paul R. Kirchgraber M.D. currently own?

As insider, Dr. Paul R. Kirchgraber M.D. owns shares in one company:

Company Title Shares Price per share Total value
Laboratory Corporation of America Holdings (LH) Executive Vice President & Chief Executive Officer of Covance Drug Devel. 12,946 $275.78 $3,570,248

What does Laboratory Corporation of America Holdings do?

Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations and accountable care organizations. It offers end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. Laboratory Corporation of America Holdings has a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.

LH logo
LH
Laboratory Corporation of America Holdings
$275.78

Paul R. Kirchgraber M.D. insider trading

Laboratory Corporation of America Holdings

Dr. Paul R. Kirchgraber M.D. has made 4 insider trades between 2020-2023, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 8,000 units of LH stock on 21 Feb 2023. As of 19 May 2023 he still owns at least 12,946 units of LH stock.

Transaction Date Security Shares Price per share Total value Source
Option
Non-qualified Stock Options 4,300 $182.51 $784,793
Option
Common Stock 4,300 $182.51 $784,793
Sale
Common Stock 4,300 $216.91 $932,709
Sale
Common Stock 8,000 $250.58 $2,004,672
Option
Common Stock 3,000 $182.51 $547,530
Option
Non-qualified Stock Options 3,000 $182.51 $547,530
Option
Common Stock 483 N/A N/A
Option
Restricted Stock Unit 483 N/A N/A
Option
Common Stock 560 N/A N/A
Option
Restricted Stock Unit 560 N/A N/A
Option
Restricted Stock Unit 443 N/A N/A
Option
Common Stock 443 N/A N/A
Option
Restricted Stock Unit 2,007 N/A N/A
Option
Common Stock 2,007 N/A N/A
Option
Restricted Stock Unit 317 N/A N/A
Option
Common Stock 317 N/A N/A
Option
Common Stock 560 N/A N/A
Option
Restricted Stock Unit 560 N/A N/A
Option
Restricted Stock Unit 443 N/A N/A
Option
Common Stock 443 N/A N/A
Option
Restricted Stock Unit 2,007 N/A N/A
Option
Common Stock 2,007 N/A N/A
Sale
Common Stock 2,500 $276.55 $691,375
Option
Common Stock 1,010 N/A N/A
Option
Restricted Stock Unit 1,010 N/A N/A
Option
Restricted Stock Unit 581 N/A N/A
Option
Common Stock 581 N/A N/A
Option
Restricted Stock Unit 560 N/A N/A
Option
Common Stock 560 N/A N/A
Sale
Common Stock 1,500 $214.14 $321,204
Option
Restricted Stock Unit 2,006 N/A N/A
Option
Common Stock 2,006 N/A N/A
Option
Common Stock 1,010 N/A N/A
Option
Restricted Stock Unit 1,010 N/A N/A
Option
Common Stock 579 N/A N/A
Option
Restricted Stock Unit 579 N/A N/A
Option
Common Stock 337 N/A N/A
Option
Restricted Stock Unit 337 N/A N/A

Laboratory Corporation of America Holdings key executives

Laboratory Corporation of America Holdings executives and other stock owners filed with the SEC:

  • Dr. Brian J. Caveney M.P.H., M.D., J.D., MPH (51) Executive Vice President, Pres of Diagnostics & Chief Medical Officer
  • Dr. Paul R. Kirchgraber M.D. (63) Executive Vice President & Chief Executive Officer of Covance Drug Devel.
  • Mr. Adam H. Schechter (60) Pres, Chief Executive Officer & Chairman
  • Mr. Glenn A. Eisenberg (64) Chief Financial Officer & Executive Vice President
  • Mr. Mark S. Schroeder (64) Executive Vice President and Pres of Diagnostics Laboratory Operations & Global Supply Chain